MCID: PST053
MIFTS: 42

Postherpetic Neuralgia

Categories: Neuronal diseases, Skin diseases

Aliases & Classifications for Postherpetic Neuralgia

MalaCards integrated aliases for Postherpetic Neuralgia:

Name: Postherpetic Neuralgia 53 36 71

Classifications:



External Ids:

KEGG 36 H01624
UMLS 71 C0032768

Summaries for Postherpetic Neuralgia

NINDS : 53 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

MalaCards based summary : Postherpetic Neuralgia is related to herpes zoster and uveitis, and has symptoms including sciatica and neuralgia. An important gene associated with Postherpetic Neuralgia is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Cytokine Signaling in Immune system. The drugs Foscarnet and Acyclovir have been mentioned in the context of this disorder. Affiliated tissues include skin, spinal cord and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

KEGG : 36 Herpes zoster (HZ) presents as a rash of 2-3 weeks duration in immunocompetent patients that is accompanied by moderate or severe pain. In some patients, pain does not resolve when the rash heals but continues for weeks and, sometimes, for months or years; this phenomenon is known as postherpetic neuralgia (PHN). PHN is the most troublesome side effect associated with HZ. Both gabapentin and pregabalin can reduce pain and improve sleep patterns in patients with PHN.

Wikipedia : 74 Postherpetic neuralgia (PHN) is neuropathic pain which occurs due to damage to a peripheral nerve caused... more...

Related Diseases for Postherpetic Neuralgia

Diseases related to Postherpetic Neuralgia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 herpes zoster 32.4 HLA-DRB1 HLA-B HLA-A
2 uveitis 29.6 HLA-B HLA-A
3 graft-versus-host disease 29.1 HLA-DRB1 HLA-B HLA-A
4 autoimmune disease 29.0 HLA-DRB1 HLA-B HLA-A
5 exanthem 11.1
6 chickenpox 11.1
7 chronic pain 10.9
8 neuropathy 10.8
9 diabetic neuropathy 10.6
10 peripheral nervous system disease 10.6
11 trigeminal neuralgia 10.5
12 paresthesia 10.5
13 pain agnosia 10.4
14 herpes zoster ophthalmicus 10.4
15 polyneuropathy 10.4
16 neuromuscular disease 10.4
17 peptic ulcer disease 10.4
18 cytokine deficiency 10.4
19 myelitis 10.3
20 fibromyalgia 10.3
21 migraine with or without aura 1 10.2
22 anxiety 10.2
23 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.2
24 osteonecrosis 10.2
25 allergic hypersensitivity disease 10.2
26 diabetic polyneuropathy 10.2
27 personality disorder 10.2
28 mental depression 10.2
29 neuritis 10.2
30 constipation 10.2
31 complex regional pain syndrome 10.2
32 dystonia 10.2
33 herpes simplex 10.2
34 back pain 10.2
35 spasticity 10.2
36 spinal cord injury 10.2
37 atrial standstill 1 10.1
38 carpal tunnel syndrome 10.1
39 erythermalgia, primary 10.1
40 hemifacial spasm, familial 10.1
41 systemic lupus erythematosus 10.1
42 rheumatoid arthritis 10.1
43 spinal arachnoiditis 10.1
44 galactorrhea 10.1
45 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
46 ocular motor apraxia 10.1
47 paine syndrome 10.1
48 ataxia and polyneuropathy, adult-onset 10.1
49 helicobacter pylori infection 10.1
50 coronary heart disease 1 10.1

Graphical network of the top 20 diseases related to Postherpetic Neuralgia:



Diseases related to Postherpetic Neuralgia

Symptoms & Phenotypes for Postherpetic Neuralgia

UMLS symptoms related to Postherpetic Neuralgia:


sciatica, neuralgia

GenomeRNAi Phenotypes related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.43 HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.43 HLA-A HLA-B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.43 HLA-A HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.43 HLA-A HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.43 HLA-A HLA-B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.43 HLA-A HLA-B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.43 HLA-A HLA-B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.43 HLA-A HLA-B
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 8.96 HLA-A HLA-B

Drugs & Therapeutics for Postherpetic Neuralgia

Drugs for Postherpetic Neuralgia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
2
Acyclovir Approved Phase 4 59277-89-3 2022
3
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
4
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
5
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
8
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
9 Anti-Retroviral Agents Phase 4
10 Reverse Transcriptase Inhibitors Phase 4
11 Anesthetics, Dissociative Phase 4
12 Anesthetics, General Phase 4
13 Anesthetics, Intravenous Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Cyclooxygenase Inhibitors Phase 4
17 Cyclooxygenase 2 Inhibitors Phase 4
18 Natriuretic Agents Phase 4
19 Sodium Potassium Chloride Symporter Inhibitors Phase 4
20 diuretics Phase 4
21 Anti-Infective Agents Phase 4
22 Antiviral Agents Phase 4
23 valacyclovir Phase 4
24 Antimanic Agents Phase 4
25 Excitatory Amino Acid Antagonists Phase 4
26 Excitatory Amino Acids Phase 4
27
Remifentanil Approved Phase 3 132875-61-7 60815
28
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Sodium citrate Approved, Investigational Phase 3 68-04-2
31
Methadone Approved Phase 3 76-99-3 4095
32
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
33
Desipramine Approved, Investigational Phase 3 50-47-5 2995
34
Nortriptyline Approved Phase 3 72-69-5 4543
35
Morphine Approved, Investigational Phase 3 57-27-2 5288826
36
Hydrocodone Approved, Illicit, Investigational Phase 3 125-29-1 5284569
37
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
38 triamcinolone acetonide Phase 2, Phase 3
39 Triamcinolone diacetate Phase 2, Phase 3
40 Triamcinolone hexacetonide Phase 2, Phase 3
41 Adrenergic Agents Phase 3
42 Anticoagulants Phase 3
43 Antidepressive Agents, Tricyclic Phase 3
44 Citrate Phase 3
45 Adjuvants, Anesthesia Phase 3
46 Chelating Agents Phase 3
47 Respiratory System Agents Phase 3
48 Antitussive Agents Phase 3
49 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
50
Levetiracetam Approved Phase 2 102767-28-2 441341

Interventional clinical trials:

(show top 50) (show all 134)
# Name Status NCT ID Phase Drugs
1 A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
2 An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
3 Lidocaine Patch for Postoperative Analgesia After Laparoscopic Cholecystectomy Unknown status NCT01485939 Phase 4
4 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Unknown status NCT02535000 Phase 4 Duloxetine;Placebo
5 The Effect of Ketamine Infusion for Reduction of Neuropathic Pain and Improvement of Quality of Life After Lumbar Surgery Unknown status NCT02154438 Phase 4 Ketamine
6 Effects of Pregabalin on Mechanical Hyperalgesia - EPOM Unknown status NCT00310583 Phase 4 Pregabalin
7 An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn ) Completed NCT01455428 Phase 4 Lyrica (pregabalin);Placebo
8 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
9 A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain Completed NCT01252160 Phase 4 QUTENZA
10 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
11 Randomized Placebo-Controlled Study of the Efficacy of Botulinum Toxin Type A (Botox) in Spontaneous Pain and Allodynia Related to Traumatic Nerve Injury or Postherpetic Neuralgia Completed NCT00527202 Phase 4 botulinum toxin A and saline
12 A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery Completed NCT02351934 Phase 4 Furosemide;Celecoxib;Gabapentin
13 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
14 Qutenza Versus Pregabalin in Subjects With Peripheral Neuropathic Pain: an Open-label, Randomized, Multicenter, Non-inferiority Efficacy and Tolerability Study Completed NCT01713426 Phase 4 Qutenza;Pregabalin
15 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
16 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
17 Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia Completed NCT00885586 Phase 4 gabapentine
18 The Effect of Epidural Steroid Use on Pain Relief in Patients With Continuous Epidural Nerve Block in Postherpetic Neuralgia Patients. Recruiting NCT03995563 Phase 4 Dexamethasone;Ropivacaine
19 Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
20 A Phase 4 Multicenter, Open-Label, Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Terminated NCT01603394 Phase 4 pregabalin
21 The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial Terminated NCT01546857 Phase 4 Placebo;Gapabentin
22 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
23 Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia -A Multicenter,Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT02868801 Phase 3 Placebo;Pregabalin SR tablet 165mg/day;Pregabalin SR tablet 330mg/day;Pregabalin SR tablet 660mg/day
24 Effect of Opioids in Neuropathic Pain in Postherpetic Patients Unknown status NCT01102101 Phase 3 Remifentanil
25 Prevention Effect of Pregabalin on Postherpetic Neuralgia: A Multicenter, Randomized, Double-blind, Controlled Trial Unknown status NCT03186443 Phase 3 Pregabalin;Gabapentin
26 Novel Non Invasive Brain Stimulation Based Treatment for Chronic Low Back Unknown status NCT02393391 Phase 2, Phase 3
27 An Open-Label Extension Safety and Efficacy Study of Pregabalin in Patients With Postherpetic Neuralgia Completed NCT00150436 Phase 3 Pregabalin
28 A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In The Treatment Of Postherpetic Neuralgia Completed NCT00424372 Phase 3 pregabalin
29 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia Completed NCT00335933 Phase 3 Gabapentin extended-release tablets
30 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia Completed NCT00636636 Phase 3 Gabapentin Extended Release tablets;Placebo
31 A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo Completed NCT00377598 Phase 2, Phase 3 TAK-583;TAK-583;TAK-583;TAK-583;Placebo
32 A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia Completed NCT00394901 Phase 3 Placebo;Pregabalin;Pregabalin;Pregabalin
33 An 11-week Randomized, Double-blind, Multi Center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (300 Mg/Day) Using A Fixed Dosing Schedule In The Treatment Of Subjects S With Pain Associated With Diabetic Peripheral Neuropathy. Completed NCT01332149 Phase 3 Pregabalin;Placebo matched with pregabalin
34 A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00115310 Phase 3 NGX-4010
35 A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00300222 Phase 3 NGX-4010
36 A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00068081 Phase 3 Capsaicin Dermal Patch
37 A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain Completed NCT00219544 Phase 3 Pregabalin (Lyrica);Pregabalin (Lyrica);Pregabalin (Lyrica);Placebo
38 A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224) Completed NCT01270828 Phase 3 Pregabalin;placebo
39 Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain. Completed NCT00414349 Phase 3 Topical analgesic;oral intake;Topical analgesic
40 A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN) Completed NCT00592904 Phase 2, Phase 3 E2007
41 A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Completed NCT00061776 Phase 2, Phase 3 Capsaicin Dermal Patch
42 A 12-Week Open-Label Study With 3 Within-Patient Double-Blind Placebo-Controlled Periods to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain Completed NCT00343733 Phase 3 OraVescent Fentanyl
43 A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
44 A Double-blind, Multicentre, Multiple-dose, Enriched Enrolment, Randomized-withdrawal, Parallel-group Phase III Study With Lido-Patch and Corresponding Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN) Completed NCT03745404 Phase 3 Lidocaine 5% medicated Plaster;Placebo Plaster
45 Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia Completed NCT00004390 Phase 3 desipramine;methadone;morphine;nortriptyline
46 Efficacy and Safety of a Novel Intradermal Live-attenuated Varicella Zoster Vaccine in Hematopoietic Stem Cell Transplantation Donors: a Randomized Double Blind Placebo-controlled Trial Completed NCT02329457 Phase 2, Phase 3
47 CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications Completed NCT00007501 Phase 3
48 A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time Completed NCT01223365 Phase 3 Hydrocodone ER
49 An Open-label, Multicenter, Multiple-dose, Phase III Study With Lidocaine 5% Medicated Plaster in Patients Suffering From Postherpetic Neuralgia Completed NCT03765697 Phase 3 Lidocaine 5% medicated plaster
50 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia Unknown status NCT00813826 Phase 2 SLC022;Placebo

Search NIH Clinical Center for Postherpetic Neuralgia

Genetic Tests for Postherpetic Neuralgia

Anatomical Context for Postherpetic Neuralgia

MalaCards organs/tissues related to Postherpetic Neuralgia:

40
Skin, Spinal Cord, Brain, Kidney, Testes, Dorsal Root Ganglion, Heart

Publications for Postherpetic Neuralgia

Articles related to Postherpetic Neuralgia:

(show top 50) (show all 1932)
# Title Authors PMID Year
1
Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. 61
31599852 2020
2
Identification of herpes zoster high-risk group using Charlson comorbidity index: A nationwide retrospective cohort study. 61
31642113 2020
3
S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. 61
31951098 2020
4
Comparison of the Analgesic Effect of Ropivacaine with Fentanyl and Ropivacaine Alone in Continuous Epidural Infusion for Acute Herpes Zoster Management: A Retrospective Study. 61
31936282 2020
5
Efficacy of continuous epidural infusion with epidural electric stimulation compared to that of conventional continuous epidural infusion for acute herpes zoster management: a retrospective study. 61
31992229 2020
6
Delayed Initiation of Supplemental Pain Management is Associated with Postherpetic Neuralgia: A Retrospective Study. 61
32013280 2020
7
Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. 61
31953880 2020
8
Vaccination of Adults in General Medical Practice. 61
31902413 2020
9
Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. 61
31705717 2020
10
Subcutaneous botulinum toxin-A injection for treating postherpetic neuralgia. 61
31769900 2020
11
Modulation of Voltage-Gated Sodium Channel Activity in Human Dorsal Root Ganglion Neurons by Herpesvirus Quiescent Infection. 61
31694955 2020
12
Patient-reported improvement in pain with pregabalin for painful diabetic neuropathy and postherpetic neuralgia is promising but needs further investigation. 61
31092541 2020
13
A clinical study of paraspinal nerve block on treatment of herpes zoster under ultrasonic guidance. 61
31348920 2019
14
Association between treatment-related early changes in psychological factors and development of postherpetic neuralgia. 61
31511988 2019
15
Complications of herpes zoster in children. 61
31628883 2019
16
The Epidemiology of Herpes Zoster and Postherpetic Neuralgia in China: Results from a Cross-Sectional Study. 61
31218562 2019
17
Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia. 61
31589557 2019
18
Test-retest and inter-examiner reliability of a novel bedside quantitative sensory testing battery in postherpetic neuralgia patients. 61
31837446 2019
19
Cervical and High-Thoracic Dorsal Root Ganglion Stimulation in Chronic Neuropathic Pain. 61
30620789 2019
20
Relationships of varicella zoster virus (VZV)-specific cell-mediated immunity and persistence of VZV DNA in saliva and the development of postherpetic neuralgia in patients with herpes zoster. 61
31286531 2019
21
Hypovitaminosis Din Postherpetic Neuralgia-High Prevalence and Inverse Association with Pain: A Retrospective Study. 61
31731694 2019
22
Population Pharmacokinetics of Pregabalin Extended-Release in Healthy Volunteers and Patients With Postherpetic Neuralgia, Fibromyalgia, and Partial-Onset Seizures. 61
31183879 2019
23
Patient characteristics and analgesic efficacy of antiviral therapy in postherpetic neuralgia. 61
31443749 2019
24
Tissue-Clearing Technique and Cutaneous Nerve Biopsies: Quantification of the Intraepidermal Nerve-Fiber Density Using Active Clarity Technique-Pressure Related Efficient and Stable Transfer of Macromolecules Into Organs. 61
31591843 2019
25
The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. 61
31541518 2019
26
VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. 61
31543415 2019
27
Comparison Of Efficacy Of Two Different Doses Of Famciclovir In The Prevention And Treatment Of Postherpetic Neuralgia. 61
31965772 2019
28
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. 61
31537443 2019
29
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. 61
31250218 2019
30
[ZHUANG Li-xing's experience of using mind-regulation acupuncture for postherpetic neuralgia]. 61
31621263 2019
31
[Systematic review and sequential analysis on treatment of herpes zoster pain mainly by fire needle therapy]. 61
31532139 2019
32
The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy. 61
31442095 2019
33
[Erratum to: Therapy of herpes zoster and postherpetic neuralgia]. 61
31482273 2019
34
Postherpetic Pruritus: A Potential Complication of Herpes Zoster Virus Infection. 61
31720141 2019
35
Suppression of neuropathic pain by selective silencing of dorsal root ganglion ectopia using nonblocking concentrations of lidocaine. 61
31095098 2019
36
Gabapentin: Change is in the Wind. 61
31462352 2019
37
Comparison of the efficacy of continuous epidural block with epidural electrical stimulation and conventional continuous epidural block for management of zoster-associated pain beyond the acute phase: A retrospective study. 61
31574800 2019
38
Complete resolution of postherpetic neuralgia following pallidotomy: case report. 61
31561224 2019
39
A rare case of a gabapentin-induced cardiomyopathy. 61
30968430 2019
40
Transcutaneous electrical nerve stimulation (TENS): a review of applications in dermatology. 61
31418608 2019
41
[Therapy of herpes zoster and postherpetic neuralgia]. 61
31270550 2019
42
Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. 61
31451524 2019
43
Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. 61
31462457 2019
44
Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. 61
31301920 2019
45
Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients: Erratum. 61
31335662 2019
46
Deep Sequencing Identification of Differentially Expressed miRNAs in the Spinal Cord of Resiniferatoxin-Treated Rats in Response to Electroacupuncture. 61
31124075 2019
47
A clinico-epidemiological multicenter study of herpes zoster in immunocompetent and immunocompromised hospitalized children. 61
31406693 2019
48
A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report. 61
31291212 2019
49
Commentary on "A Call for Caution in Prescribing Gabapentin to Individuals with Concurrent Polysubstance Abuse: A Case Report". 61
31291213 2019
50
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. 61
31287523 2019

Variations for Postherpetic Neuralgia

Expression for Postherpetic Neuralgia

Search GEO for disease gene expression data for Postherpetic Neuralgia.

Pathways for Postherpetic Neuralgia

Pathways related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 HLA-DRB1 HLA-B HLA-A
2
Show member pathways
12.82 HLA-DRB1 HLA-B HLA-A
3
Show member pathways
12.47 HLA-DRB1 HLA-B HLA-A
4
Show member pathways
12.35 HLA-DRB1 HLA-B HLA-A
5
Show member pathways
12.29 HLA-DRB1 HLA-B HLA-A
6 12.24 HLA-DRB1 HLA-B HLA-A
7
Show member pathways
12.02 HLA-B HLA-A
8 11.96 HLA-B HLA-A
9
Show member pathways
11.92 HLA-DRB1 HLA-B HLA-A
10 11.85 HLA-B HLA-A
11 11.73 HLA-B HLA-A
12 11.67 HLA-DRB1 HLA-B HLA-A
13 11.64 HLA-B HLA-A
14
Show member pathways
11.55 HLA-DRB1 HLA-A
15
Show member pathways
11.51 HLA-DRB1 HLA-A
16 11.31 HLA-DRB1 HLA-B HLA-A
17 10.97 HLA-DRB1 HLA-B HLA-A
18 10.72 HLA-B HLA-A

GO Terms for Postherpetic Neuralgia

Cellular components related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.63 HLA-DRB1 HLA-B HLA-A
2 Golgi apparatus GO:0005794 9.61 HLA-DRB1 HLA-B HLA-A
3 cell surface GO:0009986 9.43 HLA-DRB1 HLA-B HLA-A
4 early endosome membrane GO:0031901 9.4 HLA-B HLA-A
5 recycling endosome membrane GO:0055038 9.37 HLA-B HLA-A
6 phagocytic vesicle membrane GO:0030670 9.32 HLA-B HLA-A
7 MHC class I protein complex GO:0042612 9.16 HLA-B HLA-A
8 ER to Golgi transport vesicle membrane GO:0012507 9.13 HLA-DRB1 HLA-B HLA-A
9 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-DRB1 HLA-B HLA-A

Biological processes related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.58 HLA-DRB1 HLA-B HLA-A
2 immune response GO:0006955 9.54 HLA-DRB1 HLA-B HLA-A
3 regulation of immune response GO:0050776 9.48 HLA-B HLA-A
4 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.46 HLA-B HLA-A
5 type I interferon signaling pathway GO:0060337 9.43 HLA-B HLA-A
6 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.32 HLA-B HLA-A
7 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.26 HLA-B HLA-A
8 protection from natural killer cell mediated cytotoxicity GO:0042270 9.16 HLA-B HLA-A
9 interferon-gamma-mediated signaling pathway GO:0060333 9.13 HLA-DRB1 HLA-B HLA-A
10 antigen processing and presentation GO:0019882 8.8 HLA-DRB1 HLA-B HLA-A

Molecular functions related to Postherpetic Neuralgia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-DRB1 HLA-B HLA-A

Sources for Postherpetic Neuralgia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....